Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9651479 | 0.94 | MAPT (0.68) | MAPTALDH1A1LMNATSHRMEN1 | |
| SCHEMBL10430091 | 0.91 | MAPT (0.65) | MAPTALDH1A1LMNATSHRMEN1 | |
| SCHEMBL11420051 | 0.90 | MAPT (0.62) | MAPTALDH1A1LMNATSHRMEN1 | |
| SCHEMBL16742372 | 0.90 | MAPT (0.63) | MAPTALDH1A1LMNATSHRMEN1 | |
| SCHEMBL16516336 | 0.90 | MAPT (0.63) | MAPTALDH1A1LMNATSHRMEN1 | |
| SCHEMBL11545117 | 0.89 | MAPT (0.60) | MAPTALDH1A1LMNATSHRMEN1 | |
| SCHEMBL11548169 | 0.89 | MAPT (0.60) | MAPTALDH1A1LMNATSHRMEN1 | |
| SCHEMBL15063392 | 0.88 | MAPT (1.00) | MAPTALDH1A1LMNATSHRMEN1 | |
| SCHEMBL1277890 | 0.87 | MAPT (0.77) | MAPTALDH1A1LMNATSHRMEN1 | |
| SCHEMBL11545962 | 0.87 | MAPT (0.59) | MAPTALDH1A1LMNATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111362867-A | Mobile terminal, shell assembly, electrochromic material and preparation method thereof | 宁波祢若电子科技有限公司 | 2020-07-03 | — | — | CN | claimed |
| WO-2023239007-A1 | BENZIMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER OR INFECTIOUS DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-12-14 | — | — | WO | disclosed |
| CN-111362867-B | Mobile terminal, shell assembly, electrochromic material and preparation method thereof | 宁波祢若电子科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-111362867-A | Mobile terminal, shell assembly, electrochromic material and preparation method thereof | 宁波祢若电子科技有限公司 | 2020-07-03 | — | — | CN | disclosed |
| US-8951998-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2143727-B1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2797896-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT | ALLERGAN, INC. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| CN-101896483-B | Glucokinase activators and pharmaceutical compositions containing the same as active ingredients | LG LIFE SCIENCES LTD | 2013-11-20 | — | — | CN | disclosed |
| WO-2008002924-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| EP-1615613-A4 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
| EP-1615613-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004093798-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| CN-1083478-A | The method for preparing benzimidazole compound | HUBEI PHARMACEUTICAL FACTORY (CN) | 1994-03-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032528-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | MAPT 2281/4885ALDH1A1 1573/4885LMNA 3055/4885 |
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, CTSC | MAPT 4500/4885ALDH1A1 1229/4885LMNA 2349/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | MAPT 4393/4885ALDH1A1 1344/4885LMNA 2228/4885 |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | MAPT 4479/4885ALDH1A1 1352/4885LMNA 2324/4885 |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | MAPT 5/4885ALDH1A1 1479/4885LMNA 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.